Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewNMS 873 is a potent p97 ATPase (VCP) allosteric inhibitor (IC50 = 30 nM). Selective over all other AAA ATPases, HSP90 and kinases tested (IC50 >10 μM). Activates the unfolded protein response (UPR) and modulates autophagosome maturation. Exhibits antiproliferative activity in cancer cells in vitro (IC50 values are 400 and 700 nM for HCT116 and HeLa cells respectively). Reduces p97-sensitization to trypsin digestion.
NMS 873 is also offered as part of the Tocriscreen 2.0 Max. Find out more about compound libraries available from Tocris.
M. Wt | 520.67 |
Formula | C27H28N4O3S2 |
Storage | Store at +4°C |
Purity | ≥98% (HPLC) |
CAS Number | 1418013-75-8 |
PubChem ID | 71521142 |
InChI Key | UJGTUKMAJVCBIS-UHFFFAOYSA-N |
Smiles | CC1=C(C2=CC=C(S(C)(=O)=O)C=C2)C=CC(OCC3=NN=C(N3C4=CN=CC=C4)SC5CCCC5)=C1 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solvent | Max Conc. mg/mL | Max Conc. mM | |
---|---|---|---|
Solubility | |||
DMSO | 52.07 | 100 |
The following data is based on the product molecular weight 520.67. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.92 mL | 9.6 mL | 19.21 mL |
5 mM | 0.38 mL | 1.92 mL | 3.84 mL |
10 mM | 0.19 mL | 0.96 mL | 1.92 mL |
50 mM | 0.04 mL | 0.19 mL | 0.38 mL |
References are publications that support the biological activity of the product.
Magnaghi et al (2013) Covalent and allosteric inhibitors of the ATPase VCP/p97 induce cancer cell death. Nat.Chem.Biol. 9 548 PMID: 23892893
Anderson et al (2015) Targeting the AAA ATPase p97 as an approach to treat cancer through disruption of protein homeostasis. Cancer Cell 28 653 PMID: 26555175
Polucci et al (2013) Alkylsulfanyl-1,2,4-triazoles, a new class of allosteric valosine containing protein inhibitors. Synthesis and structure-activity relationships. J.Med.Chem. 56 437 PMID: 23245311
If you know of a relevant reference for NMS 873, please let us know.
Keywords: NMS 873, NMS 873 supplier, NMS873, Potent, selective, valosine, containing, protein, VCP, p97, allosteric, inhibitors, inhibits, unfolded, response, UPR, autophagosome, maturation, antiproliferative, anticancer, Autophagy, Other, ER, stress/UPR, ATPase, Translocation, 6180, Tocris Bioscience
Citations are publications that use Tocris products. Selected citations for NMS 873 include:
Keith et al (2022) Compounds activating VCP D1 ATPase enhance both autophagic and proteasomal neurotoxic protein clearance. Nat Commun 13 4146 PMID: 35842429
Manu et al (2020) Protein translocation and retro-translocation across the endoplasmic reticulum are crucial to inflammatory effector CD4+ T cell function. Cytokine 129 154944 PMID: 32146280
Yong et al (2020) Tandem Deubiquitination and Acetylation of SPRTN Promotes DNA-Protein Crosslink Repair and Protects against Aging. Mol Cell 79 824-835.e5 PMID: 32649882
Oscar et al (2021) USP7 and VCPFAF1 define the SUMO/Ubiquitin landscape at the DNA replication fork. Cell Rep 37 109819 PMID: 34644576
Do you know of a great paper that uses NMS 873 from Tocris? Please let us know.
Average Rating: 3 (Based on 1 Review.)
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by:
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
This poster summarizes the main metabolic pathways in cancer cells and highlights potential targets for cancer therapeutics. Genetic changes and epigenetic modifications in cancer cells alter the regulation of cellular metabolic pathways providing potential cancer therapeutic targets.